Skip to main content
Erschienen in: Supportive Care in Cancer 11/2018

22.05.2018 | Commentary

The application of neuromuscular electrical stimulation (NMES) in cancer rehabilitation: current prescription, pitfalls, and future directions

verfasst von: Dominic O’Connor, Brian Caulfield

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

The plethora of treatment complications associated with cancer can be offset by regular exercise participation; however, adherence to current guidelines is poor, in particular in those unable or not allowed to participate in voluntary exercise due to their underlying disease. Alternative therapies such as neuromuscular electrical stimulation (NMES) are promising although previous results in cancer survivors have been equivocal. This is likely in response to methodological issues such as inappropriate NMES prescription. Therefore, the aim of this commentary is to propose three key areas which should be addressed to increase NMES effectiveness in cancer rehabilitation; (1) NMES exercise should target both the neuromuscular and cardiovascular systems through low- and high-frequency modalities, (2) technological advancements such as mobile app-based systems should be leveraged to improve at-home monitoring of home-based NMES exercise, and (3) prescription and progression should follow the fundamental principles of exercise to overcome the heterogeneity in daily physiological, functional, and psychological factors faced by survivors. Addressing these three key areas in future studies may help improve NMES exercise effectiveness and accelerate patient rehabilitation.
Literatur
3.
Zurück zum Zitat Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvão DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen V, Schwartz AL, American College of Sports Medicine (2010) American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42:1409–1426CrossRef Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvão DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen V, Schwartz AL, American College of Sports Medicine (2010) American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42:1409–1426CrossRef
8.
Zurück zum Zitat Cenik F, Schoberwalter D, Keilani M, Maehr B, Wolzt M, Marhold M, Crevenna R (2016) Neuromuscular electrical stimulation of the thighs in cardiac patients with implantable cardioverter defibrillators. Wien Klin Wochenschr 128:802–808CrossRef Cenik F, Schoberwalter D, Keilani M, Maehr B, Wolzt M, Marhold M, Crevenna R (2016) Neuromuscular electrical stimulation of the thighs in cardiac patients with implantable cardioverter defibrillators. Wien Klin Wochenschr 128:802–808CrossRef
11.
Zurück zum Zitat Maddocks M, Halliday V, Chauhan A, Taylor V, Nelson A, Sampson C, Byrne A, Griffiths G, Wilcock A (2013) Neuromuscular electrical stimulation of the quadriceps in patients with non-small cell lung cancer receiving palliative chemotherapy: a randomized phase II study. PLoS One 8:1–8. https://doi.org/10.1371/journal.pone.0086059 CrossRef Maddocks M, Halliday V, Chauhan A, Taylor V, Nelson A, Sampson C, Byrne A, Griffiths G, Wilcock A (2013) Neuromuscular electrical stimulation of the quadriceps in patients with non-small cell lung cancer receiving palliative chemotherapy: a randomized phase II study. PLoS One 8:1–8. https://​doi.​org/​10.​1371/​journal.​pone.​0086059 CrossRef
13.
Zurück zum Zitat Minogue CM, Caulfield BM, Reilly RB (2007) What are the electrical stimulation design parameters for maximum VO 2 aimed at cardio-pulmonary rehabilitation? In: Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings. pp 2428–2431 Minogue CM, Caulfield BM, Reilly RB (2007) What are the electrical stimulation design parameters for maximum VO 2 aimed at cardio-pulmonary rehabilitation? In: Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings. pp 2428–2431
15.
Zurück zum Zitat Caulfield B, Prendergast A, Rainsford G, Minogue C (2013) Self directed home based electrical muscle stimulation training improves exercise tolerance and strength in healthy elderly. Conf Proc Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Annu Conf 2013:7036–7039. https://doi.org/10.1109/EMBC.2013.6611178 CrossRef Caulfield B, Prendergast A, Rainsford G, Minogue C (2013) Self directed home based electrical muscle stimulation training improves exercise tolerance and strength in healthy elderly. Conf Proc Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Annu Conf 2013:7036–7039. https://​doi.​org/​10.​1109/​EMBC.​2013.​6611178 CrossRef
18.
Zurück zum Zitat Chughtai M, Piuzzi N, Yakubek G, Khlopas A, Sodhi N, Sultan AA, Nasir S, Yates BST, Bhave A, Mont MA (2017) Use of an app-controlled neuromuscular electrical stimulation system for improved self-management of knee conditions and reduced costs. Surg Technol Int 31:221–226PubMed Chughtai M, Piuzzi N, Yakubek G, Khlopas A, Sodhi N, Sultan AA, Nasir S, Yates BST, Bhave A, Mont MA (2017) Use of an app-controlled neuromuscular electrical stimulation system for improved self-management of knee conditions and reduced costs. Surg Technol Int 31:221–226PubMed
Metadaten
Titel
The application of neuromuscular electrical stimulation (NMES) in cancer rehabilitation: current prescription, pitfalls, and future directions
verfasst von
Dominic O’Connor
Brian Caulfield
Publikationsdatum
22.05.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 11/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4269-z

Weitere Artikel der Ausgabe 11/2018

Supportive Care in Cancer 11/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.